Manoj Kumbhare, Siddhi Chandak*, Arshad Shaikh, Sakshi Velhal, Aishwarya Dukare, Harshali gode, Nishant Pagere, Bhagwan Ide

Department of Pharmaceutical Chemistry, SMBT College of Pharmacy, Dhamangaon, Nashik – 422403, India

* Address    for  Correspondence:

Siddhi M. Chandak,

Department of Pharmaceutical Chemistry, SMBT College of

Pharmacy, Dhamangaon, Nashik – 422403, Affiliated to Savitribai

Phule Pune University, India

Email: siddhimchandak@gmail.com

ORCID ID: 0009-0006-7860-2388

Abstract

Sotagliflozin, a novel dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1/2), represents a promising therapeutic advancement for managing diabetes mellitus. By inhibiting SGLT1 in the small intestine and SGLT2 in the kidneys, sotagliflozin uniquely improves glycemic control through reduced postprandial glucose absorption and enhanced urinary glucose excretion. This dual mechanism has shown significant benefits for both type 1 and type 2 diabetes, including reduced insulin requirements, better glycemic control, weight loss, and improved cardiovascular and renal outcomes. Clinical trials have highlighted its potential to mitigate the risks of diabetic complications such as heart failure and chronic kidney disease. However, its use is associated with some side effects, including gastrointestinal disturbances, urinary tract infections, and an elevated risk of diabetic ketoacidosis. This review explores the chemistry, pharmacology, and therapeutic implications of sotagliflozin, emphasizing its unique dual-target approach and potential to address unmet needs in diabetes management.

Keywords  Sotagliflozin, Diabetes mellitus, Pharmacological, Phytochemicals

PDF  Unlocking the Potential of Sotagliflozin in Diabetes Mellitus targeting SGLT 1 & SGLT 2: A Comprehensive Review.pdf